Clinical Trial: A Phase II Trial to Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS in HIV- Negative Women

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07810062) titled 'A Phase II Trial to Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS in HIV- Negative Women' on July 28.

Brief Summary: A double blinded, Randomized, Placebo- controlled phase II trial to assess extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV- negative women

Study Start Date: Aug. 28, 2023

Study Type: INTERVENTIONAL

Condition: To Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS Monoclonal Antibodies in HIV-negative Women

Intervention: BIOLOGICAL: Broad band monoclonal antibodies named as CAP256V2LS and VRC07- 523LS

HIV prev...